首页 > 最新文献

Psoriasis (Auckland, N.Z.)最新文献

英文 中文
Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives. 阿巴接受治疗成人银屑病关节炎:患者选择和观点。
Pub Date : 2018-07-11 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S146076
Ashley Noisette, Marc C Hochberg

Psoriatic arthritis (PsA) is a heterogeneous disease with several clinical subtypes including peripheral arthritis, dactylitis, enthesitis, nail disease, and axial arthritis. Nonsteroidal anti-inflammatory drugs, glucocorticoids, and conventional disease-modifying agents are used as first line in the treatment of active PsA. For moderate-to-severe PsA failing conventional therapy, antitumor necrosis factor inhibitors have historically been the drugs of choice. In recent years, novel interleukin-23/interleukin-17 pathway targets such as ustekinumab and secukinumab, and phosphodiesterase-4 inhibitor apremilast have been approved for use in the United States and Europe. Two sets of recommendations for the management of PsA were published in 2016 with consideration for these newer therapies. Since then, the results from a Phase III randomized controlled trial demonstrated that abatacept has efficacy in the treatment of PsA. Abatacept, a cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4)-Ig human fusion protein, acts to prevent naïve T-cell activation through the inhibition of the critical CD28 co-stimulatory signal. In the 2017 Active Psoriatic Arthritis Randomized Trial (ASTRAEA), 424 participants were randomized 1:1 to receive subcutaneous abatacept 125 mg weekly versus placebo. At week 24, 39.4% of those who received abatacept achieved a minimum of 20% improvement in the American College of Rheumatology (ACR) response compared to 22.3% in the placebo arm, a statistically significant finding (P<0.001). The 2011 Phase II study published by Mease et al demonstrated statistically significant improvements in the ACR20 response by week 169 in participants treated with intravenous abatacept 10 mg/kg (48%) and 30/10 mg/kg (42%) when compared with placebo (19%). This article reviews the data supporting the efficacy of abatacept in the management of PsA and attempts to place this agent in the context of other biologic disease-modifying antirheumatic drugs and targeted small molecules used in the treatment of patients with PsA.

银屑病关节炎(PsA)是一种异质性疾病,有几种临床亚型,包括外周关节炎、趾炎、鼻炎、甲病和轴性关节炎。非甾体抗炎药、糖皮质激素和常规的疾病调节剂是治疗活动性PsA的一线用药。对于常规治疗失败的中重度PsA,抗肿瘤坏死因子抑制剂历来是首选药物。近年来,新的白介素-23/白介素-17途径靶点,如ustekinumab和secukinumab,以及磷酸二酯酶-4抑制剂apremilast已被批准在美国和欧洲使用。2016年发表了两套针对PsA管理的建议,考虑了这些新疗法。从那时起,一项III期随机对照试验的结果表明,阿巴接受在治疗PsA方面有疗效。Abatacept是一种细胞毒性t淋巴细胞相关抗原4 (CTLA-4)-Ig人融合蛋白,通过抑制关键的CD28共刺激信号来阻止naïve t细胞活化。在2017年的活动性银屑病关节炎随机试验(ASTRAEA)中,424名参与者按1:1的比例随机分配,接受每周125毫克皮下注射阿巴肽和安慰剂。在第24周,39.4%接受abataccept的患者在美国风湿病学会(ACR)反应中至少改善了20%,而安慰剂组为22.3%,这是一个具有统计学意义的发现(P
{"title":"Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives.","authors":"Ashley Noisette,&nbsp;Marc C Hochberg","doi":"10.2147/PTT.S146076","DOIUrl":"https://doi.org/10.2147/PTT.S146076","url":null,"abstract":"<p><p>Psoriatic arthritis (PsA) is a heterogeneous disease with several clinical subtypes including peripheral arthritis, dactylitis, enthesitis, nail disease, and axial arthritis. Nonsteroidal anti-inflammatory drugs, glucocorticoids, and conventional disease-modifying agents are used as first line in the treatment of active PsA. For moderate-to-severe PsA failing conventional therapy, antitumor necrosis factor inhibitors have historically been the drugs of choice. In recent years, novel interleukin-23/interleukin-17 pathway targets such as ustekinumab and secukinumab, and phosphodiesterase-4 inhibitor apremilast have been approved for use in the United States and Europe. Two sets of recommendations for the management of PsA were published in 2016 with consideration for these newer therapies. Since then, the results from a Phase III randomized controlled trial demonstrated that abatacept has efficacy in the treatment of PsA. Abatacept, a cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4)-Ig human fusion protein, acts to prevent naïve T-cell activation through the inhibition of the critical CD28 co-stimulatory signal. In the 2017 Active Psoriatic Arthritis Randomized Trial (ASTRAEA), 424 participants were randomized 1:1 to receive subcutaneous abatacept 125 mg weekly versus placebo. At week 24, 39.4% of those who received abatacept achieved a minimum of 20% improvement in the American College of Rheumatology (ACR) response compared to 22.3% in the placebo arm, a statistically significant finding (<i>P</i><0.001). The 2011 Phase II study published by Mease et al demonstrated statistically significant improvements in the ACR20 response by week 169 in participants treated with intravenous abatacept 10 mg/kg (48%) and 30/10 mg/kg (42%) when compared with placebo (19%). This article reviews the data supporting the efficacy of abatacept in the management of PsA and attempts to place this agent in the context of other biologic disease-modifying antirheumatic drugs and targeted small molecules used in the treatment of patients with PsA.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S146076","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36336807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. 监测甲氨蝶呤诱导的银屑病患者肝纤维化:瞬时弹性成像的效用。
Pub Date : 2018-05-09 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S141629
Harriet S Cheng, Marius Rademaker

Increasingly, existing evidence indicates that methotrexate-associated liver injury is related to comorbid risk factors such as diabetes, alcoholism, and obesity, rather than to methotrexate itself. Despite this fact, significant effort continues to be expended in the monitoring of low-dose methotrexate in patients with psoriasis. The gold standard investigation has been liver biopsy, but this is associated with significant morbidity and mortality. As methotrexate-induced liver injury is uncommon, the risk/benefit ratio of liver biopsy has been questioned. Fortunately, a number of new technologies have been developed for the diagnosis of chronic liver disease, including transient elastography (TE). TE is a type of shear wave ultrasound elastography, which measures the speed of shear waves used to estimate hepatic tissue stiffness. Several meta-analyses show very high pooled sensitivity and specificity for the diagnosis of hepatic cirrhosis (87% and 91%, respectively) in a variety of chronic liver disorders. It has a negative predictive value for cirrhosis of >90% and a positive predictive value of 75%. Recent European guidelines now advocate the use of TE as the first-line test for the assessment of fibrosis in alcohol- or hepatitis-related liver disease, including nonalcoholic fatty liver disease (NAFLD). As the prevalence of obesity and metabolic syndrome, including NAFLD, is significantly elevated in patients with psoriasis, TE may be worth considering as a routine investigation for any patient with psoriasis. Although high-quality studies comparing TE with standard liver biopsy in the monitoring of psoriatics on low-dose methotrexate are lacking, the evidence from multiple small cohort studies and case series demonstrates its effectiveness. A recent Australasian position statement recommends that TE should be considered as a routine investigation for monitoring methotrexate therapy, repeated every 3 years if kPa <7.5 and yearly if kPa >7.5. Liver biopsy should be considered for patients with a kPa >9.5.

越来越多的现有证据表明,甲氨蝶呤相关的肝损伤与合并症危险因素(如糖尿病、酒精中毒和肥胖)有关,而与甲氨蝶呤本身无关。尽管如此,在监测银屑病患者的低剂量甲氨蝶呤方面仍花费了大量的努力。金标准调查是肝活检,但这与显著的发病率和死亡率相关。由于甲氨蝶呤引起的肝损伤并不常见,肝活检的风险/收益比一直受到质疑。幸运的是,许多诊断慢性肝病的新技术已经被开发出来,包括瞬时弹性成像(TE)。TE是一种剪切波超声弹性成像,它测量剪切波的速度,用于估计肝组织的刚度。几项荟萃分析显示,在各种慢性肝脏疾病中,肝硬化诊断的综合敏感性和特异性非常高(分别为87%和91%)。对肝硬化的阴性预测值>90%,阳性预测值为75%。最近的欧洲指南提倡使用TE作为评估酒精或肝炎相关肝病(包括非酒精性脂肪性肝病(NAFLD))纤维化的一线试验。由于银屑病患者中肥胖和代谢综合征(包括NAFLD)的患病率显著升高,TE可能值得考虑作为任何银屑病患者的常规检查。虽然目前还缺乏比较TE与标准肝活检在低剂量甲氨蝶呤监测银屑病患者中的疗效的高质量研究,但来自多个小队列研究和病例系列的证据表明其有效性。澳大利亚最近的一项立场声明建议,TE应被视为监测甲氨蝶呤治疗的常规调查,如果kPa为7.5,则每3年重复一次。kPa >9.5的患者应考虑肝活检。
{"title":"Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography.","authors":"Harriet S Cheng,&nbsp;Marius Rademaker","doi":"10.2147/PTT.S141629","DOIUrl":"https://doi.org/10.2147/PTT.S141629","url":null,"abstract":"<p><p>Increasingly, existing evidence indicates that methotrexate-associated liver injury is related to comorbid risk factors such as diabetes, alcoholism, and obesity, rather than to methotrexate itself. Despite this fact, significant effort continues to be expended in the monitoring of low-dose methotrexate in patients with psoriasis. The gold standard investigation has been liver biopsy, but this is associated with significant morbidity and mortality. As methotrexate-induced liver injury is uncommon, the risk/benefit ratio of liver biopsy has been questioned. Fortunately, a number of new technologies have been developed for the diagnosis of chronic liver disease, including transient elastography (TE). TE is a type of shear wave ultrasound elastography, which measures the speed of shear waves used to estimate hepatic tissue stiffness. Several meta-analyses show very high pooled sensitivity and specificity for the diagnosis of hepatic cirrhosis (87% and 91%, respectively) in a variety of chronic liver disorders. It has a negative predictive value for cirrhosis of >90% and a positive predictive value of 75%. Recent European guidelines now advocate the use of TE as the first-line test for the assessment of fibrosis in alcohol- or hepatitis-related liver disease, including nonalcoholic fatty liver disease (NAFLD). As the prevalence of obesity and metabolic syndrome, including NAFLD, is significantly elevated in patients with psoriasis, TE may be worth considering as a routine investigation for any patient with psoriasis. Although high-quality studies comparing TE with standard liver biopsy in the monitoring of psoriatics on low-dose methotrexate are lacking, the evidence from multiple small cohort studies and case series demonstrates its effectiveness. A recent Australasian position statement recommends that TE should be considered as a routine investigation for monitoring methotrexate therapy, repeated every 3 years if kPa <7.5 and yearly if kPa >7.5. Liver biopsy should be considered for patients with a kPa >9.5.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S141629","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36118050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 34
Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry. 来自冰岛ICEBIO注册中心的结果显示,低起始剂量的英夫利昔单抗治疗银屑病关节炎的效果与标准剂量的阿达木单抗或依那西普相同。
Pub Date : 2018-05-04 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S161522
Bjorn Gudbjornsson, Arni Jon Geirsson, Niels Steen Krogh

Objective: To explore differences in response to a low dosage regimen of infliximab with an escalating dosage in comparison to a standard dosage of etanercept and adalimumab in patients with psoriatic arthritis (PsA).

Methods: Biologically naïve PsA patients who were beginning anti-TNF-α therapy were selected from the ICEBIO registry. Demographics and clinical differences were compared in four treatment groups: infliximab <4 mg/kg; infliximab >4 mg/kg; etanercept or adalimumab at baseline and on follow-up (6 and 12 months, last visit). The Kruskal-Wallis rank sum test was used for comparison of the groups and the Wilcoxon test to compare the two infliximab dosage regimens.

Results: One hundred and eighty-five patients (61% female) were identified; 84 patients received infliximab, 66 etanercept, and 35 adalimumab. A total of 19% of the patients treated with infliximab escalated their dosage ≥4 mg/kg. No significant differences were observed at baseline in respect to visual analog scale (VAS) pain, VAS fatigue, Health Assessment Questionnaire, C-reactive protein (CRP), numbers of swollen or tender joints, or Disease Activity Score (DAS) 28-CRP values. A similar treatment response was observed in all four treatment groups on follow-up.

Conclusion: In respect to treatment effects, a low dosage of infliximab with possible escalating dosage is acceptable for the majority of PsA patients who are in need of biological treatment.

目的:探讨银屑病关节炎(PsA)患者对英夫利昔单抗低剂量方案的反应差异,并与标准剂量依那西普和阿达木单抗进行比较。方法:从ICEBIO登记处选择生物学naïve开始抗tnf -α治疗的PsA患者。比较4个治疗组的人口统计学和临床差异:英夫利昔单抗4 mg/kg;依那西普或阿达木单抗基线和随访(6个月和12个月,最后一次就诊)。组间比较采用Kruskal-Wallis秩和检验,两种英夫利昔单抗给药方案的比较采用Wilcoxon检验。结果:共发现185例患者(61%为女性);84例患者接受英夫利昔单抗、66例依那西普和35例阿达木单抗治疗。接受英夫利昔单抗治疗的患者中,有19%的患者将剂量增加到≥4mg /kg。在基线时,在视觉模拟量表(VAS)疼痛、VAS疲劳、健康评估问卷、c -反应蛋白(CRP)、肿胀或压痛关节数量或疾病活动评分(DAS) 28-CRP值方面没有观察到显著差异。在随访中,所有四个治疗组均观察到类似的治疗反应。结论:就治疗效果而言,对于大多数需要生物治疗的PsA患者来说,低剂量英夫利昔单抗并可能增加剂量是可以接受的。
{"title":"Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry.","authors":"Bjorn Gudbjornsson,&nbsp;Arni Jon Geirsson,&nbsp;Niels Steen Krogh","doi":"10.2147/PTT.S161522","DOIUrl":"https://doi.org/10.2147/PTT.S161522","url":null,"abstract":"<p><strong>Objective: </strong>To explore differences in response to a low dosage regimen of infliximab with an escalating dosage in comparison to a standard dosage of etanercept and adalimumab in patients with psoriatic arthritis (PsA).</p><p><strong>Methods: </strong>Biologically naïve PsA patients who were beginning anti-TNF-α therapy were selected from the ICEBIO registry. Demographics and clinical differences were compared in four treatment groups: infliximab <4 mg/kg; infliximab >4 mg/kg; etanercept or adalimumab at baseline and on follow-up (6 and 12 months, last visit). The Kruskal-Wallis rank sum test was used for comparison of the groups and the Wilcoxon test to compare the two infliximab dosage regimens.</p><p><strong>Results: </strong>One hundred and eighty-five patients (61% female) were identified; 84 patients received infliximab, 66 etanercept, and 35 adalimumab. A total of 19% of the patients treated with infliximab escalated their dosage ≥4 mg/kg. No significant differences were observed at baseline in respect to visual analog scale (VAS) pain, VAS fatigue, Health Assessment Questionnaire, C-reactive protein (CRP), numbers of swollen or tender joints, or Disease Activity Score (DAS) 28-CRP values. A similar treatment response was observed in all four treatment groups on follow-up.</p><p><strong>Conclusion: </strong>In respect to treatment effects, a low dosage of infliximab with possible escalating dosage is acceptable for the majority of PsA patients who are in need of biological treatment.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S161522","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36102402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis. HLA-Cw6基因分型在ustekinumab治疗下银屑病患者预后预测中的有限临床应用:一项单中心回顾性分析
Pub Date : 2018-03-23 eCollection Date: 2017-01-01 DOI: 10.2147/PTT.S161437
Florian Anzengruber, Adhideb Ghosh, Julia-Tatjana Maul, Mathias Drach, Alexander A Navarini

Purpose: Several studies have suggested that an HLA-Cw6+ allele can predict an improved outcome of treatment in psoriasis patients. The aim of the study was to assess whether the published association between HLA-Cw6 allele carriers and response to ustekinumab has the potential to impact treatment decisions.

Patients and methods: Differences in Psoriasis Activity and Severity Index 50, 75, and 90; Nail Psoriasis Severity Index; and Dermatology Life Quality Index at 16 weeks were evaluated between HLA-Cw6 allele carriers vs. non-carriers. Thirty patients with moderate-to-severe psoriasis under treatment with ustekinumab were included in our study.

Results: There was no difference between the two groups with respect to Psoriasis Activity and Severity Index 50, 75, and 90 or in terms of change in Nail Psoriasis Severity Index or Dermatology Life Quality Index.

Conclusion: In our retrospectively analyzed cohort, we could not detect the previously reported better response in HLA-Cw6+ vs. HLA-Cw6- patients.

目的:几项研究表明,HLA-Cw6+等位基因可以预测银屑病患者治疗结果的改善。该研究的目的是评估已发表的HLA-Cw6等位基因携带者与ustekinumab应答之间的关联是否有可能影响治疗决策。患者和方法:银屑病活动性和严重程度指数50、75、90的差异指甲银屑病严重程度指数;在HLA-Cw6等位基因携带者与非携带者之间评估16周时的皮肤病学生活质量指数。我们的研究纳入了30例接受ustekinumab治疗的中重度牛皮癣患者。结果:两组在银屑病活动度和严重程度指数50、75、90、指甲银屑病严重程度指数和皮肤科生活质量指数变化方面无差异。结论:在我们回顾性分析的队列中,我们没有发现先前报道的HLA-Cw6+与HLA-Cw6-患者的更好反应。
{"title":"Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis.","authors":"Florian Anzengruber,&nbsp;Adhideb Ghosh,&nbsp;Julia-Tatjana Maul,&nbsp;Mathias Drach,&nbsp;Alexander A Navarini","doi":"10.2147/PTT.S161437","DOIUrl":"https://doi.org/10.2147/PTT.S161437","url":null,"abstract":"<p><strong>Purpose: </strong>Several studies have suggested that an HLA-Cw6+ allele can predict an improved outcome of treatment in psoriasis patients. The aim of the study was to assess whether the published association between HLA-Cw6 allele carriers and response to ustekinumab has the potential to impact treatment decisions.</p><p><strong>Patients and methods: </strong>Differences in Psoriasis Activity and Severity Index 50, 75, and 90; Nail Psoriasis Severity Index; and Dermatology Life Quality Index at 16 weeks were evaluated between HLA-Cw6 allele carriers vs. non-carriers. Thirty patients with moderate-to-severe psoriasis under treatment with ustekinumab were included in our study.</p><p><strong>Results: </strong>There was no difference between the two groups with respect to Psoriasis Activity and Severity Index 50, 75, and 90 or in terms of change in Nail Psoriasis Severity Index or Dermatology Life Quality Index.</p><p><strong>Conclusion: </strong>In our retrospectively analyzed cohort, we could not detect the previously reported better response in HLA-Cw6+ vs. HLA-Cw6- patients.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S161437","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36065361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Targeting IL-23 in psoriasis: current perspectives. 靶向IL-23治疗牛皮癣:目前的观点。
Pub Date : 2018-01-04 eCollection Date: 2018-01-01 DOI: 10.2147/PTT.S98893
Christina Fotiadou, Elizabeth Lazaridou, Eleni Sotiriou, Demetrios Ioannides

The recent advances in the understanding of psoriasis pathogenesis have clarified the pivotal role of interleukin (IL)-23. It is a heterodimeric cytokine consisting of two subunits, the unique p19 and the p40, which are shared with IL-12. The basic role of IL-23 in psoriasis is the activation and maintenance of the T-helper 17 pathway. New research findings indicate that IL-23 is more important than IL-12 in the pathogenesis of psoriasis. Based on that background, the selective targeting of the IL-23p19 subunit emerged as an attractive therapeutic option and led to the development of a new category of biologic agents. Three monoclonal antibodies that selectively inhibit the IL-23p19 subunit, guselkumab, tildrakizumab, and risankizumab, are in the pipeline for the treatment of moderate-to-severe psoriasis. In this article, we review the most recent efficacy and safety data regarding these IL-23p19 inhibitors.

近年来对银屑病发病机制的研究进展明确了白细胞介素-23在银屑病发病机制中的关键作用。它是一种异二聚体细胞因子,由两个亚基组成,独特的p19和p40,它们与IL-12共享。IL-23在银屑病中的基本作用是激活和维持t -辅助性17通路。新的研究结果表明,IL-23在银屑病的发病机制中比IL-12更重要。基于这一背景,选择性靶向IL-23p19亚基成为一种有吸引力的治疗选择,并导致了一类新的生物制剂的发展。三种选择性抑制IL-23p19亚基的单克隆抗体guselkumab、tildrakizumab和risankizumab正在开发中,用于治疗中重度牛皮癣。在本文中,我们回顾了这些IL-23p19抑制剂的最新疗效和安全性数据。
{"title":"Targeting IL-23 in psoriasis: current perspectives.","authors":"Christina Fotiadou,&nbsp;Elizabeth Lazaridou,&nbsp;Eleni Sotiriou,&nbsp;Demetrios Ioannides","doi":"10.2147/PTT.S98893","DOIUrl":"https://doi.org/10.2147/PTT.S98893","url":null,"abstract":"<p><p>The recent advances in the understanding of psoriasis pathogenesis have clarified the pivotal role of interleukin (IL)-23. It is a heterodimeric cytokine consisting of two subunits, the unique p19 and the p40, which are shared with IL-12. The basic role of IL-23 in psoriasis is the activation and maintenance of the T-helper 17 pathway. New research findings indicate that IL-23 is more important than IL-12 in the pathogenesis of psoriasis. Based on that background, the selective targeting of the IL-23p19 subunit emerged as an attractive therapeutic option and led to the development of a new category of biologic agents. Three monoclonal antibodies that selectively inhibit the IL-23p19 subunit, guselkumab, tildrakizumab, and risankizumab, are in the pipeline for the treatment of moderate-to-severe psoriasis. In this article, we review the most recent efficacy and safety data regarding these IL-23p19 inhibitors.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S98893","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35829135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 58
Drug-induced psoriasis: clinical perspectives. 药物性牛皮癣:临床观点。
Pub Date : 2017-12-07 eCollection Date: 2017-01-01 DOI: 10.2147/PTT.S126727
Deepak Mw Balak, Enes Hajdarbegovic

Exposure to certain drugs can elicit an induction or exacerbation of psoriasis. Although well-conducted systematic studies on drug-related psoriasis are mostly lacking, traditionally strong associations have been documented for beta-blockers, lithium, antimalarial drugs such as (hydroxy)chloroquine, interferons, imiquimod, and terbinafine. More recently, new associations have been reported for monoclonal antibody- and small-molecule-based targeted therapies used for oncological and immunological indications, such as tumor necrosis factor-alpha antagonists and anti-programmed cell death protein 1 immune checkpoint inhibitors. Recognizing potential drug-related psoriasis is of clinical relevance to allow an optimal management of psoriasis. However, in clinical practice, identifying medication-related exacerbations and induction of psoriasis can be challenging. The clinical and histopathological features of drug-provoked psoriasis may differ little from that of "classical" nondrug-related forms of psoriasis. In addition, the latency period between start of the medication and onset of psoriasis can be significantly long for some drugs. Assessment of the Naranjo adverse drug reaction probability scale could be used as a practical tool to better differentiate drug-related psoriasis. The first step in the management of drug-related psoriasis is cessation and replacement of the offending drug when deemed clinically possible. However, the induced psoriasis skin lesions may persist after treatment withdrawal. Additional skin-directed treatment options for drug-related psoriasis follows the conventional psoriasis treatment guidelines and includes topical steroids and vitamin D analogs, ultraviolet phototherapy, systemic treatments, such as acitretin, methotrexate, and fumaric acid esters, and biological treatments.

暴露于某些药物可诱发或加重牛皮癣。虽然对药物相关性银屑病的系统研究大多缺乏,但传统上已证实-受体阻滞剂、锂、抗疟疾药物如(羟基)氯喹、干扰素、咪喹莫特和特比萘芬有很强的相关性。最近,针对肿瘤和免疫学适应症的单克隆抗体和小分子靶向治疗,如肿瘤坏死因子- α拮抗剂和抗程序性细胞死亡蛋白1免疫检查点抑制剂,已经报道了新的关联。认识到潜在的药物相关性牛皮癣是临床相关,允许牛皮癣的最佳管理。然而,在临床实践中,确定与药物相关的银屑病恶化和诱导可能具有挑战性。药物引起的银屑病的临床和组织病理学特征可能与“经典”非药物相关形式的银屑病差别不大。此外,从开始用药到牛皮癣发作的潜伏期对某些药物来说可能很长。评估Naranjo药物不良反应概率量表可作为更好地鉴别药物相关性银屑病的实用工具。治疗药物相关性牛皮癣的第一步是在临床认为可能的情况下停止并更换致病药物。然而,诱导的牛皮癣皮损可能在停药后持续存在。药物相关性银屑病的其他皮肤定向治疗选择遵循传统的银屑病治疗指南,包括局部类固醇和维生素D类似物,紫外线光疗,全身治疗,如阿维甲素,甲氨蝶呤和富马酸酯,以及生物治疗。
{"title":"Drug-induced psoriasis: clinical perspectives.","authors":"Deepak Mw Balak,&nbsp;Enes Hajdarbegovic","doi":"10.2147/PTT.S126727","DOIUrl":"https://doi.org/10.2147/PTT.S126727","url":null,"abstract":"<p><p>Exposure to certain drugs can elicit an induction or exacerbation of psoriasis. Although well-conducted systematic studies on drug-related psoriasis are mostly lacking, traditionally strong associations have been documented for beta-blockers, lithium, antimalarial drugs such as (hydroxy)chloroquine, interferons, imiquimod, and terbinafine. More recently, new associations have been reported for monoclonal antibody- and small-molecule-based targeted therapies used for oncological and immunological indications, such as tumor necrosis factor-alpha antagonists and anti-programmed cell death protein 1 immune checkpoint inhibitors. Recognizing potential drug-related psoriasis is of clinical relevance to allow an optimal management of psoriasis. However, in clinical practice, identifying medication-related exacerbations and induction of psoriasis can be challenging. The clinical and histopathological features of drug-provoked psoriasis may differ little from that of \"classical\" nondrug-related forms of psoriasis. In addition, the latency period between start of the medication and onset of psoriasis can be significantly long for some drugs. Assessment of the Naranjo adverse drug reaction probability scale could be used as a practical tool to better differentiate drug-related psoriasis. The first step in the management of drug-related psoriasis is cessation and replacement of the offending drug when deemed clinically possible. However, the induced psoriasis skin lesions may persist after treatment withdrawal. Additional skin-directed treatment options for drug-related psoriasis follows the conventional psoriasis treatment guidelines and includes topical steroids and vitamin D analogs, ultraviolet phototherapy, systemic treatments, such as acitretin, methotrexate, and fumaric acid esters, and biological treatments.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S126727","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35781733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 88
Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives. 间充质干细胞在牛皮癣发病机制中的作用:目前的观点。
Pub Date : 2017-11-27 eCollection Date: 2017-01-01 DOI: 10.2147/PTT.S108311
Anna Campanati, Veronica Consales, Monia Orciani, Katia Giuliodori, Giulia Ganzetti, Ivan Bobyr, Giulia Sorgentoni, Roberto di Primio, Annamaria Offidani

Mesenchymal stem cells (MSCs) are multipotent nonhematopoietic stromal cells studied for their properties and importance in management of several skin diseases. This review collects and analyzes the emerging published data, which describe the function of MSCs in the pathogenesis of psoriasis.

间充质干细胞(MSCs)是一种多能的非造血基质细胞,因其特性和在几种皮肤疾病治疗中的重要性而被研究。本文收集并分析了新近发表的关于MSCs在牛皮癣发病机制中的作用的数据。
{"title":"Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives.","authors":"Anna Campanati,&nbsp;Veronica Consales,&nbsp;Monia Orciani,&nbsp;Katia Giuliodori,&nbsp;Giulia Ganzetti,&nbsp;Ivan Bobyr,&nbsp;Giulia Sorgentoni,&nbsp;Roberto di Primio,&nbsp;Annamaria Offidani","doi":"10.2147/PTT.S108311","DOIUrl":"https://doi.org/10.2147/PTT.S108311","url":null,"abstract":"<p><p>Mesenchymal stem cells (MSCs) are multipotent nonhematopoietic stromal cells studied for their properties and importance in management of several skin diseases. This review collects and analyzes the emerging published data, which describe the function of MSCs in the pathogenesis of psoriasis.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S108311","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35781736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. ixekizumab治疗中重度斑块型银屑病的临床应用
Pub Date : 2017-11-16 eCollection Date: 2017-01-01 DOI: 10.2147/PTT.S129792
Sahil Sekhon, Caleb Jeon, Mio Nakamura, Di Yan, Ladan Afifi, Tina Bhutani, Ethan Levin

Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate-severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.

寻常型牛皮癣是一种慢性、免疫介导的全身性疾病,在美国有affectŝ7.5百万患者。它可以用许多疗法来治疗,通常是联合治疗,包括外敷、光疗、口服系统和生物制剂。生物制剂针对银屑病发病机制中涉及的免疫系统的特定成分,包括tnf - α, IL-12, IL-17和IL-23。生物制剂ixekizumab在美国被批准用于治疗中重度斑块性银屑病,靶向IL-17。本文综述了IL-17在银屑病中的作用,ixekizumab靶向该细胞因子的机制,以及ixekizumab的临床应用。
{"title":"Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.","authors":"Sahil Sekhon,&nbsp;Caleb Jeon,&nbsp;Mio Nakamura,&nbsp;Di Yan,&nbsp;Ladan Afifi,&nbsp;Tina Bhutani,&nbsp;Ethan Levin","doi":"10.2147/PTT.S129792","DOIUrl":"https://doi.org/10.2147/PTT.S129792","url":null,"abstract":"<p><p>Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate-severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S129792","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35781732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. 甲型银屑病:临床特征、发病机制、鉴别诊断及治疗。
Pub Date : 2017-10-16 eCollection Date: 2017-01-01 DOI: 10.2147/PTT.S126281
Eckart Haneke

Psoriasis is the skin disease that most frequently affects the nails. Depending on the very nail structure involved, different clinical nail alterations can be observed. Irritation of the apical matrix results in psoriatic pits, mid-matrix involvement may cause leukonychia, whole matrix affection may lead to red lunulae or severe nail dystrophy, nail bed involvement may cause salmon spots, subungual hyperkeratosis, and splinter hemorrhages, and psoriasis of the distal nail bed and hyponychium causes onycholysis whereas that of the proximal nail fold causes psoriatic paronychia. The more extensive the involvement, the more severe is the nail destruction. Pustular psoriasis may be seen as yellow spots under the nail or, in case of acrodermatitis continua suppurativa, as an insidious progressive loss of the nail organ. Nail psoriasis has a severe impact on quality of life and may interfere with professional and other activities. Management includes patient counseling, avoidance of stress and strain to the nail apparatus, and different types of treatment. Topical therapy may be tried but is rarely sufficiently efficient. Perilesional injections with corticosteroids and methotrexate are often beneficial but may be painful and cannot be applied to many nails. All systemic treatments clearing widespread skin lesions usually also clear the nail lesions. Recently, biologicals were introduced into nail psoriasis treatment and found to be very effective. However, their use is restricted to severe cases due to high cost and potential systemic adverse effects.

银屑病是影响指甲最常见的皮肤病。根据所涉及的指甲结构,可以观察到不同的临床指甲变化。顶端基质的刺激会导致银屑病凹坑,基质中层受累可能会导致白质甲沟炎,全基质受累可能导致新月形红或严重的指甲营养不良,甲床受累可能会引起鲑鱼斑、舌下角化过度和碎片出血,远端甲床和甲沟炎的银屑病引起甲沟溶解,而近端甲襞的银屑病引起银屑病性甲沟炎。参与的范围越广,破坏指甲的情况就越严重。脓疱性银屑病可能表现为指甲下的黄色斑点,或者,在持续化脓性肢端皮炎的情况下,表现为指甲器官的隐性进行性丧失。指甲银屑病严重影响生活质量,并可能干扰职业和其他活动。管理包括患者咨询、避免指甲器械的压力和紧张以及不同类型的治疗。局部治疗可以尝试,但很少足够有效。病灶周围注射皮质类固醇和甲氨蝶呤通常是有益的,但可能会疼痛,不能用于许多指甲。所有清除广泛皮肤损伤的全身治疗通常也会清除指甲损伤。最近,生物制剂被引入指甲银屑病的治疗中,并被发现是非常有效的。然而,由于成本高和潜在的系统不良反应,它们的使用仅限于严重病例。
{"title":"Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.","authors":"Eckart Haneke","doi":"10.2147/PTT.S126281","DOIUrl":"10.2147/PTT.S126281","url":null,"abstract":"<p><p>Psoriasis is the skin disease that most frequently affects the nails. Depending on the very nail structure involved, different clinical nail alterations can be observed. Irritation of the apical matrix results in psoriatic pits, mid-matrix involvement may cause leukonychia, whole matrix affection may lead to red lunulae or severe nail dystrophy, nail bed involvement may cause salmon spots, subungual hyperkeratosis, and splinter hemorrhages, and psoriasis of the distal nail bed and hyponychium causes onycholysis whereas that of the proximal nail fold causes psoriatic paronychia. The more extensive the involvement, the more severe is the nail destruction. Pustular psoriasis may be seen as yellow spots under the nail or, in case of acrodermatitis continua suppurativa, as an insidious progressive loss of the nail organ. Nail psoriasis has a severe impact on quality of life and may interfere with professional and other activities. Management includes patient counseling, avoidance of stress and strain to the nail apparatus, and different types of treatment. Topical therapy may be tried but is rarely sufficiently efficient. Perilesional injections with corticosteroids and methotrexate are often beneficial but may be painful and cannot be applied to many nails. All systemic treatments clearing widespread skin lesions usually also clear the nail lesions. Recently, biologicals were introduced into nail psoriasis treatment and found to be very effective. However, their use is restricted to severe cases due to high cost and potential systemic adverse effects.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S126281","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35782339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 66
Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis. 单中心、非介入性临床试验,评估基于二甲二酮的医疗器械在银屑病或头皮癣患者局部应用后促进鳞片去除的安全性、有效性和耐受性。
Pub Date : 2017-06-15 eCollection Date: 2017-01-01 DOI: 10.2147/PTT.S130295
Ulrich R Hengge, Kristina Röschmann, Henning Candler

Introduction: Psoriasis is a frequent inflammatory skin disease affecting ~2%-3% of the population in western countries. Scaling of the psoriatic lesions is the most impairing symptom in patients with psoriasis. In contrast to conventional keratolytic treatment concepts containing salicylic acid or urea, a dimeticone-based medical device (Loyon®) removes scales in a physical way without any pharmacological effect.

Objective: To assess the efficacy and tolerability of a dimeticone-based medical device in removal of scales in patients with psoriasis corporis/capitis under real-life conditions.

Methods: Forty patients with psoriasis capitis or corporis were included and received once-daily treatments for 7 days. Clinical assessment of the psoriasis area severity index score (psoriasis corporis) and the psoriasis scalp severity index score (psoriasis capitis) was performed and evaluated at baseline, after 3 and 7 days of treatment. Baseline scaling scores and redness scores were calculated for two target lesions of the scalp or the body on a 5-point scale each.

Results: For the primary efficacy variable scaling score, a statistically significant decrease was observed after treatment, with a relative reduction in scaling of 36.8% after 7 days of treatment within patients affected by psoriasis capitis. Treatment success was achieved in 76.8% of patients with psoriasis capitis, and time to treatment success was evaluated to be 4.14 days for these patients and 4.33 days for patients suffering from psoriasis corporis.

Conclusion: In conclusion, this trial demonstrated that the dimeticone-based medical device is a safe, well-tolerated, practicable, and efficient keratolytic compound, which can be well implemented in and recommended for standard therapy of psoriasis.

简介:银屑病是一种常见的炎症性皮肤病,在西方国家约占人口的2%-3%。银屑病皮损的脱屑是银屑病患者最严重的症状。与传统的含有水杨酸或尿素的角化治疗概念相反,基于二甲基苯胺的医疗设备(Loyon®)以物理方式去除鳞片,而不会产生任何药理作用。目的:评价基于二甲二酮的医疗器械在现实条件下用于牛皮癣/头皮癣患者去鳞的疗效和耐受性。方法:选取40例银屑病患者,每日1次,连续治疗7 d。临床评估牛皮癣区域严重程度指数评分(牛皮癣公司)和牛皮癣头皮严重程度指数评分(牛皮癣头皮癣)在基线,治疗3天和7天后进行和评估。对头皮或身体的两个目标病变分别以5分制计算基线评分和发红评分。结果:治疗后主要疗效变量评分有统计学意义的降低,银屑病患者治疗7天后评分相对降低36.8%。头皮癣患者治疗成功的比例为76.8%,头皮癣患者治疗成功的时间为4.14天,公司型牛皮癣患者治疗成功的时间为4.33天。结论:本试验表明,基于二美二酮的医疗器械是一种安全、耐受性好、实用、高效的角化化合物,可以很好地实施并推荐用于银屑病的标准治疗。
{"title":"Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis.","authors":"Ulrich R Hengge,&nbsp;Kristina Röschmann,&nbsp;Henning Candler","doi":"10.2147/PTT.S130295","DOIUrl":"https://doi.org/10.2147/PTT.S130295","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a frequent inflammatory skin disease affecting ~2%-3% of the population in western countries. Scaling of the psoriatic lesions is the most impairing symptom in patients with psoriasis. In contrast to conventional keratolytic treatment concepts containing salicylic acid or urea, a dimeticone-based medical device (Loyon<sup>®</sup>) removes scales in a physical way without any pharmacological effect.</p><p><strong>Objective: </strong>To assess the efficacy and tolerability of a dimeticone-based medical device in removal of scales in patients with psoriasis corporis/capitis under real-life conditions.</p><p><strong>Methods: </strong>Forty patients with psoriasis capitis or corporis were included and received once-daily treatments for 7 days. Clinical assessment of the psoriasis area severity index score (psoriasis corporis) and the psoriasis scalp severity index score (psoriasis capitis) was performed and evaluated at baseline, after 3 and 7 days of treatment. Baseline scaling scores and redness scores were calculated for two target lesions of the scalp or the body on a 5-point scale each.</p><p><strong>Results: </strong>For the primary efficacy variable scaling score, a statistically significant decrease was observed after treatment, with a relative reduction in scaling of 36.8% after 7 days of treatment within patients affected by psoriasis capitis. Treatment success was achieved in 76.8% of patients with psoriasis capitis, and time to treatment success was evaluated to be 4.14 days for these patients and 4.33 days for patients suffering from psoriasis corporis.</p><p><strong>Conclusion: </strong>In conclusion, this trial demonstrated that the dimeticone-based medical device is a safe, well-tolerated, practicable, and efficient keratolytic compound, which can be well implemented in and recommended for standard therapy of psoriasis.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S130295","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35782338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
期刊
Psoriasis (Auckland, N.Z.)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1